FDA committee votes against Mallinckrodt's jaundice candidate in newborns

FDA's Gastrointestinal Drugs Advisory Committee and Pediatric Advisory Committee voted 21-3 that the risk-benefit profile of stannsoporfin does not support its approval to treat newborns ≥35 weeks who...